A citation-based method for searching scientific literature

Evgeny N Imyanitov, Aglaya G Iyevleva, Evgeny V Levchenko. Crit Rev Oncol Hematol 2021
Times Cited: 12







List of co-cited articles
26 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.
Ferdinandos Skoulidis, Michael E Goldberg, Danielle M Greenawalt, Matthew D Hellmann, Mark M Awad, Justin F Gainor, Alexa B Schrock, Ryan J Hartmaier, Sally E Trabucco, Laurie Gay,[...]. Cancer Discov 2018
494
25

Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer.
Jürgen Wolf, Takashi Seto, Ji-Youn Han, Noemi Reguart, Edward B Garon, Harry J M Groen, Daniel S W Tan, Toyoaki Hida, Maja de Jonge, Sergey V Orlov,[...]. N Engl J Med 2020
96
25

Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.
Paul K Paik, Enriqueta Felip, Remi Veillon, Hiroshi Sakai, Alexis B Cortot, Marina C Garassino, Julien Mazieres, Santiago Viteri, Helene Senellart, Jan Van Meerbeeck,[...]. N Engl J Med 2020
99
25

Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer.
Alexander Drilon, Geoffrey R Oxnard, Daniel S W Tan, Herbert H F Loong, Melissa Johnson, Justin Gainor, Caroline E McCoach, Oliver Gautschi, Benjamin Besse, Byoung C Cho,[...]. N Engl J Med 2020
101
25

MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.
Mark M Awad, Geoffrey R Oxnard, David M Jackman, Daniel O Savukoski, Dimity Hall, Priyanka Shivdasani, Jennifer C Heng, Suzanne E Dahlberg, Pasi A Jänne, Suman Verma,[...]. J Clin Oncol 2016
309
25

KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.
David S Hong, Marwan G Fakih, John H Strickler, Jayesh Desai, Gregory A Durm, Geoffrey I Shapiro, Gerald S Falchook, Timothy J Price, Adrian Sacher, Crystal S Denlinger,[...]. N Engl J Med 2020
199
25


PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers.
J K Sabari, G C Leonardi, C A Shu, R Umeton, J Montecalvo, A Ni, R Chen, J Dienstag, C Mrad, I Bergagnini,[...]. Ann Oncol 2018
104
25


Non-small cell lung cancer: current treatment and future advances.
Cecilia Zappa, Shaker A Mousa. Transl Lung Cancer Res 2016
532
16

Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration.
Alexander Drilon, Jeffrey W Clark, Jared Weiss, Sai-Hong Ignatius Ou, D Ross Camidge, Benjamin J Solomon, Gregory A Otterson, Liza C Villaruz, Gregory J Riely, Rebecca S Heist,[...]. Nat Med 2020
96
16

The METeoric rise of MET in lung cancer.
Alex Friedlaender, Alexander Drilon, Giuseppe Luigi Banna, Solange Peters, Alfredo Addeo. Cancer 2020
6
33

Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies.
Doron Lipson, Marzia Capelletti, Roman Yelensky, Geoff Otto, Alex Parker, Mirna Jarosz, John A Curran, Sohail Balasubramanian, Troy Bloom, Kristina W Brennan,[...]. Nat Med 2012
583
16

Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018.
Florian Guisier, Catherine Dubos-Arvis, Florent Viñas, Helene Doubre, Charles Ricordel, Stanislas Ropert, Henri Janicot, Marie Bernardi, Pierre Fournel, Régine Lamy,[...]. J Thorac Oncol 2020
59
16

Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial.
Alexander Drilon, Natasha Rekhtman, Maria Arcila, Lu Wang, Andy Ni, Melanie Albano, Martine Van Voorthuysen, Romel Somwar, Roger S Smith, Joseph Montecalvo,[...]. Lancet Oncol 2016
232
16

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
Robert C Doebele, Alexander Drilon, Luis Paz-Ares, Salvatore Siena, Alice T Shaw, Anna F Farago, Collin M Blakely, Takashi Seto, Byung Chul Cho, Diego Tosi,[...]. Lancet Oncol 2020
245
16

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.
J Mazieres, A Drilon, A Lusque, L Mhanna, A B Cortot, L Mezquita, A A Thai, C Mascaux, S Couraud, R Veillon,[...]. Ann Oncol 2019
232
16

Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma.
Giuseppe Lamberti, Elisa Andrini, Monia Sisi, Alessandro Rizzo, Claudia Parisi, Alessandro Di Federico, Francesco Gelsomino, Andrea Ardizzoni. Crit Rev Oncol Hematol 2020
15
16

Targeting MET in Lung Cancer: Will Expectations Finally Be MET?
Alexander Drilon, Federico Cappuzzo, Sai-Hong Ignatius Ou, D Ross Camidge. J Thorac Oncol 2017
160
16

KIF5B-RET fusions in lung adenocarcinoma.
Takashi Kohno, Hitoshi Ichikawa, Yasushi Totoki, Kazuki Yasuda, Masaki Hiramoto, Takao Nammo, Hiromi Sakamoto, Koji Tsuta, Koh Furuta, Yoko Shimada,[...]. Nat Med 2012
537
16

Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping.
Paul K Paik, Alexander Drilon, Pang-Dian Fan, Helena Yu, Natasha Rekhtman, Michelle S Ginsberg, Laetitia Borsu, Nikolaus Schultz, Michael F Berger, Charles M Rudin,[...]. Cancer Discov 2015
363
16

Precision Targeted Therapy with BLU-667 for RET-Driven Cancers.
Vivek Subbiah, Justin F Gainor, Rami Rahal, Jason D Brubaker, Joseph L Kim, Michelle Maynard, Wei Hu, Qiongfang Cao, Michael P Sheets, Douglas Wilson,[...]. Cancer Discov 2018
155
16

Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.
D Ross Camidge, Hye Ryun Kim, Myung-Ju Ahn, James Chih-Hsin Yang, Ji-Youn Han, Jong-Seok Lee, Maximilian J Hochmair, Jacky Yu-Chung Li, Gee-Chen Chang, Ki Hyeong Lee,[...]. N Engl J Med 2018
314
16

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Jean-Charles Soria, Yuichiro Ohe, Johan Vansteenkiste, Thanyanan Reungwetwattana, Busyamas Chewaskulyong, Ki Hyeong Lee, Arunee Dechaphunkul, Fumio Imamura, Naoyuki Nogami, Takayasu Kurata,[...]. N Engl J Med 2018
16

A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER).
Yuankai Shi, Joseph Siu-Kie Au, Sumitra Thongprasert, Sankar Srinivasan, Chun-Ming Tsai, Mai Trong Khoa, Karin Heeroma, Yohji Itoh, Gerardo Cornelio, Pan-Chyr Yang. J Thorac Oncol 2014
657
16

TIMER2.0 for analysis of tumor-infiltrating immune cells.
Taiwen Li, Jingxin Fu, Zexian Zeng, David Cohen, Jing Li, Qianming Chen, Bo Li, X Shirley Liu. Nucleic Acids Res 2020
264
16

RNAi mediated silencing of Nanog expression suppresses the growth of human colorectal cancer stem cells.
Chen Zhang, Yuanyuan Zhao, Yongjing Yang, Chunlian Zhong, Tianju Ji, Jinyue Duan, Yi Wang. Biochem Biophys Res Commun 2021
1
100

Anti-angiogenic-specific adverse events in patients with non-small cell lung cancer treated with nintedanib and docetaxel.
Martin Reck, Anders Mellemgaard, Joachim von Pawel, Maya Gottfried, Igor Bondarenko, Ying Cheng, Kostas Zarogoulidis, Alexander Luft, Jaafar Bennouna, José Barrueco,[...]. Lung Cancer 2015
19
8

RNases H: Structure and mechanism.
Malwina Hyjek, Małgorzata Figiel, Marcin Nowotny. DNA Repair (Amst) 2019
33
8

Highly stable polyglutamate derivatives/siRNA polyplex efficiently down-relegate survivin expression and augment the efficacy of cisplatin.
Zhongjuan Wang, Haijuan Zou, Zirui Wang, Jiamin Wu, Zhongsheng Xia, Min Feng. Int J Pharm 2016
15
8

Small RNA combination therapy for lung cancer.
Wen Xue, James E Dahlman, Tuomas Tammela, Omar F Khan, Sabina Sood, Apeksha Dave, Wenxin Cai, Leilani M Chirino, Gillian R Yang, Roderick Bronson,[...]. Proc Natl Acad Sci U S A 2014
159
8

Structural Analysis of Human Argonaute-2 Bound to a Modified siRNA Guide.
Nicole T Schirle, Garth A Kinberger, Heather F Murray, Walt F Lima, Thazha P Prakash, Ian J MacRae. J Am Chem Soc 2016
38
8

Angiogenesis Inhibitors in NSCLC.
Anna Manzo, Agnese Montanino, Guido Carillio, Raffaele Costanzo, Claudia Sandomenico, Nicola Normanno, Maria Carmela Piccirillo, Gennaro Daniele, Francesco Perrone, Gaetano Rocco,[...]. Int J Mol Sci 2017
33
8

The human secretome.
Mathias Uhlén, Max J Karlsson, Andreas Hober, Anne-Sophie Svensson, Julia Scheffel, David Kotol, Wen Zhong, Abdellah Tebani, Linnéa Strandberg, Fredrik Edfors,[...]. Sci Signal 2019
57
8

Argonaute2 is the catalytic engine of mammalian RNAi.
Jidong Liu, Michelle A Carmell, Fabiola V Rivas, Carolyn G Marsden, J Michael Thomson, Ji-Joon Song, Scott M Hammond, Leemor Joshua-Tor, Gregory J Hannon. Science 2004
8

Splicing-Correcting Therapy for SMA.
Lili Wan, Gideon Dreyfuss. Cell 2017
18
8

Downregulation of miR-506-3p Facilitates EGFR-TKI Resistance through Induction of Sonic Hedgehog Signaling in Non-Small-Cell Lung Cancer Cell Lines.
Inamul Haque, Hameem I Kawsar, Hannah Motes, Mukut Sharma, Snigdha Banerjee, Sushanta K Banerjee, Andrew K Godwin, Chao H Huang. Int J Mol Sci 2020
2
50

Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer.
Charles M Rudin, Mark Kozloff, Philip C Hoffman, Martin J Edelman, Robyn Karnauskas, Ronald Tomek, Livia Szeto, Everett E Vokes. J Clin Oncol 2004
111
8

5' UTR m(6)A Promotes Cap-Independent Translation.
Kate D Meyer, Deepak P Patil, Jun Zhou, Alexandra Zinoviev, Maxim A Skabkin, Olivier Elemento, Tatyana V Pestova, Shu-Bing Qian, Samie R Jaffrey. Cell 2015
736
8

Base editing: advances and therapeutic opportunities.
Elizabeth M Porto, Alexis C Komor, Ian M Slaymaker, Gene W Yeo. Nat Rev Drug Discov 2020
17
8

3'-Terminal 2'-O-methylation of lung cancer miR-21-5p enhances its stability and association with Argonaute 2.
Hongwei Liang, Zichen Jiao, Weiwei Rong, Shuang Qu, Zhicong Liao, Xinlei Sun, Yao Wei, Quan Zhao, Jun Wang, Yuan Liu,[...]. Nucleic Acids Res 2020
11
9

MicroRNAs and the cell cycle.
María José Bueno, Marcos Malumbres. Biochim Biophys Acta 2011
251
8


PTBP1-Mediated Alternative Splicing Regulates the Inflammatory Secretome and the Pro-tumorigenic Effects of Senescent Cells.
Athena Georgilis, Sabrina Klotz, Christopher J Hanley, Nicolas Herranz, Benedikt Weirich, Beatriz Morancho, Ana Carolina Leote, Luana D'Artista, Suchira Gallage, Marco Seehawer,[...]. Cancer Cell 2018
68
8

AXL mediates resistance to cetuximab therapy.
Toni M Brand, Mari Iida, Andrew P Stein, Kelsey L Corrigan, Cara M Braverman, Neha Luthar, Mahmoud Toulany, Parkash S Gill, Ravi Salgia, Randall J Kimple,[...]. Cancer Res 2014
120
8

The Impact of Adipose Tissue-Derived miRNAs in Metabolic Syndrome, Obesity, and Cancer.
Gabriella Simões Heyn, Luís Henrique Corrêa, Kelly Grace Magalhães. Front Endocrinol (Lausanne) 2020
10
10

Molecular mechanisms of RNA interference.
Ross C Wilson, Jennifer A Doudna. Annu Rev Biophys 2013
513
8

A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma.
Ranjana Advani, Prema Peethambaram, Bert L Lum, George A Fisher, Lynn Hartmann, Harry J Long, Joanne Halsey, Jon T Holmlund, Andrew Dorr, Branimir I Sikic. Cancer 2004
55
8


Beyond Blocking: Engineering RNAi-Mediated Targeted Immune Checkpoint Nanoblocker Enables T-Cell-Independent Cancer Treatment.
Xiaoyan Han, Linlin Wang, Ting Li, Jiahui Zhang, Dailiang Zhang, Jili Li, Yinghao Xia, Yanlan Liu, Weihong Tan. ACS Nano 2020
3
33


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.